Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Diadema Partners Lp
Form 13F · Q2 2026

Diadema Partners Lp

CIK 2026172Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$791M
Reported book value
149
Positions
7
Quarters on record
Top 50
Positions

Diadema Partners Lp — holdings

Top 50 positions of 149, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1UTHR United Therapeutics Corp Del52,989+94.1%$29M3.6%
2RVMD Revolution Medicines Inc139,218+72.1%$26M3.3%
3ABIVAX SA Abivax Sa163,644+115.5%$22M2.7%
4COGT Cogent Biosciences Inc493,664+52.9%$19M2.4%
5BMRN Biomarin Pharmaceutical Inc312,846+111.1%$18M2.3%
6VKTX Viking Therapeutics Inc441,808−15.9%$17M2.2%
7EWTX Edgewise Therapeutics Inc272,214—$11M1.4%
8KOD Kodiak Sciences Inc218,117+13.0%$8M1.1%
9IMCR Immunocore Hldgs Plc254,863+31.9%$8M1.0%
10FDMT 4D Molecular Therapeutics In571,107—$8M1.0%
11RCUS Arcus Biosciences Inc223,810−6.0%$7M0.9%
12JNJ Johnson & Johnson22,000−59.1%$6M0.7%
13NVO Novo-Nordisk A S100,000+586.0%$5M0.6%
14CRVS Corvus Pharmaceuticals Inc294,811+20.4%$4M0.6%
15RLAY Relay Therapeutics Inc230,677—$4M0.5%
16ZYME Zymeworks Inc142,132+0.0%$4M0.5%
17BIOA Bioage Labs Inc146,334+143.9%$4M0.5%
18TSHA Taysha Gene Therapies Inc522,619—$4M0.4%
19NRIX Nurix Therapeutics Inc121,539—$3M0.4%
20CRBP Corbus Pharmaceuticals Hldgs301,264−31.5%$3M0.4%
21INDIVIOR PHARMACEUTICALS INC Indivior Pharmaceuticals Inc67,512−5.4%$3M0.4%
22IVA Inventiva Sa740,786+110.2%$3M0.3%
23ORKA Oruka Therapeutics Inc27,799—$3M0.3%
24PCVX Vaxcyte Inc45,071+79.8%$3M0.3%
25RLMD Relmada Therapeutics Inc361,367+79.9%$3M0.3%
26VERA Vera Therapeutics Inc57,608—$2M0.3%
27CTNM Contineum Therapeutics Inc119,733—$2M0.2%
28BCYC Bicycle Therapeutics Plc462,724−2.9%$2M0.2%
29GLUE Monte Rosa Therapeutics Inc78,391−58.1%$2M0.2%
30VRDN Viridian Therapeutics Inc100,000—$2M0.2%
31MGNX Macrogenics Inc374,403−37.6%$2M0.2%
32PROQR THRAPEUTICS N V Proqr Thrapeutics N V926,016+414.2%$2M0.2%
33SPRB Spruce Biosciences Inc30,000+200.0%$2M0.2%
34ARDX Ardelyx Inc303,025—$2M0.2%
35CUE Cue Biopharma Inc48,369—$2M0.2%
36MLYS Mineralys Therapeutics Inc56,347+113.9%$2M0.2%
37PRTA Prothena Corp Plc149,482—$1M0.2%
38VYGR Voyager Therapeutics Inc413,642−2.4%$1M0.2%
39UNCY Unicycive Therapeutics Inc303,676+186.3%$1M0.2%
40PHAT Phathom Pharmaceuticals Inc129,950+137.8%$1M0.2%
41SYRE Spyre Therapeutics Inc15,000—$1M0.2%
42CYBIN INC Cybin Inc200,000—$1M0.2%
43EQ Equillium Inc400,282−7.7%$1M0.2%
44XERS Xeris Biopharma Holdings Inc132,746+0.0%$1M0.1%
45PHVS Pharvaris N V29,321+0.0%$1M0.1%
46HRMY Harmony Biosciences Hldgs In26,864−71.1%$978,1180.1%
47RNAC Cartesian Therapeutics Inc87,057—$907,1340.1%
48RIGL Rigel Pharmaceuticals Inc22,816—$892,5620.1%
49SMMT Summit Therapeutics Inc60,000—$874,2000.1%
50PGEN Precigen Inc135,293+144.7%$771,1700.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.